Lipsosomal Amphotericin B for Treatment of Cutaneous Leishmaniasis

Glenn Wortmann,* Michael Zapor, Roseanne Ressner, Susan Fraser, Josh Hartzell, Joseph Pierson, Amy Weintrob, and Alan Magill

Infectious Diseases Service, Walter Reed Army Medical Center, Washington, District of Columbia; Uniformed Services University of the Health Sciences, Bethesda, Maryland; Infectious Diseases Clinical Research Program, Bethesda, Maryland; Guthrie Army Health Clinic, Fort Drum, New York; Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland

Abstract. Treatment options for cutaneous leishmaniasis in the United States are problematic because the available products are either investigational, toxic, and/or of questionable effectiveness. A retrospective review of patients receiving liposomal amphotericin B through the Walter Reed Army Medical Center for the treatment of cutaneous leishmaniasis during 2007–2009 was conducted. Twenty patients who acquired disease in five countries and with five different strains of *Leishmania* were treated, of whom 19 received a full course of treatment. Sixteen (84%) of 19 experienced a cure with the initial treatment regimen. Three patients did not fully heal after an initial treatment course, but were cured with additional dosing. Acute infusion-related reactions occurred in 25% and mild renal toxicity occurred in 45% of patients. Although the optimum dosing regimen is undefined and the cost and toxicity may limit widespread use, liposomal amphotericin B is a viable treatment alternative for cutaneous leishmaniasis.

INTRODUCTION

Leishmaniasis refers to a broad spectrum of disease caused by protozoan parasites belonging to the genus *Leishmania*. Cutaneous leishmaniasis (CL) usually occurs in the Old World and is caused by *Leishmania major* and *L. tropica*. In the New World, it is caused by *L.* (*Viannia*) *braziliensis*, *L.* (*V.*) *panamensis*, and *L.* *mexicana*. Infected patients typically have a non-healing ulcer on exposed skin but the diversity of clinical manifestations includes all dermatologic syndromes.1

The treatment of CL in the United States is problematic because there is no U.S. Food and Drug Administration (FDA)–approved drug for this indication. Sodium stibogluconate (Pentostam; Glaxo-Smith-Kline, Brentford, United Kingdom) is the therapy suggested by many experts and is available to clinicians under an Investigational New Drug (IND) protocol from the Centers for Disease Control and Prevention (CDC). For U.S. Department of Defense beneficiaries, Pentostam is available under an IND protocol at the Walter Reed Army Medical Center (WRAMC) in Washington, DC, and more than 500 patients have been treated at WRAMC since 2000. The recommended treatment of moderate-to-severe CL requires daily intravenous infusions (20 doses) and is associated with increased levels of pancreatic enzymes in > 90% of patients, increased levels of liver enzymes in > 50%, and significant arthralgias and myalgias in > 50%. Rarer side effects include development of herpes zoster infection during or shortly after treatment and electrocardiographic changes.4,5 A safety release from the manufacturer in 2006 warned of particular matter in the vials (from an interaction with the stopper), and required that the medication be strained through a filter before administration.6

Because Pentostam is not an approved drug in the United States, the administration of Pentostam is only possible under an approved protocol administered under Institutional Review Board oversight and an IND application with the FDA with the attendant documentation for sponsor regulatory oversight. Pentostam can only be given with individual written informed consent, and it is often a time-consuming challenge to explain why Pentostam is the drug of choice for CL and yet not FDA approved for this indication. Because of the rarity of CL in the United States, few clinicians and nurses are experienced with the administration and side effect profile of Pentostam and they may seek expert consultation. For busy clinicians, the combination of the additional documentation burden, written informed consent, an extensive side effect profile that requires close monitoring and inexperience with the drug present significant limitations to the use of Pentostam.

Amphotericin B deoxycholate has been used as a second-line treatment for mucosal leishmaniasis and CL (especially with pentavalent antimony treatment failures) in the New World since the early 1960s. The systemic and renal toxicity, cost, and difficulty of intravenous administration in leishmaniasis-endemic areas prevented more widespread use. The introduction of lipid-associated amphotericin B products with less renal toxicity has enabled more widespread use.

In 1997, the FDA approved liposomal amphotericin B (AmBisome; Astellas Pharma US Inc, Deerfield, IL) for treatment of visceral leishmaniasis in otherwise immunocompetent adults at the dose of 3 mg/kg/day for 7 doses given on days 1–5, 14, and 21 (total dose = 21 mg/kg). In a search for a more tolerable therapy for CL, some clinicians have reported success with the use of AmBisome (Table 1).6–10 Most of these reports include only one or small numbers of patients, include persons with immunosuppressive conditions, persons who had shown initial treatment failures with pentavalent antimony, or report efficacy against just one species of *Leishmania* or from just one geographic region. We report our experience with the use of AmBisome as drug therapy for the treatment of CL in 20 non-immune, immunocompetent returning travelers.

METHODS

A retrospective chart review was conducted on all patients receiving AmBisome for laboratory-confirmed CL who were either directly managed or managed in consultation with the WRAMC Infectious Disease Service during 2007–2009. Documentation of health care within the Department of Defense is accomplished through a centralized electronic medical record system termed the Armed Forces Health Longitudinal Technology Application system. Patients receiving health care by any Department of Defense health care...
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment regimen</th>
<th>Total dose of AmBisome (mg/kg)</th>
<th>No. patients evaluated/age/sex</th>
<th>Clinical manifestation</th>
<th>Disease-endemic area resident or returned traveler (non-immune)</th>
<th>Immunocompromised</th>
<th>Prior anti-leishmanial drug treatment</th>
<th>Country in which acquired</th>
<th>Species</th>
<th>Duration of follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amato and others⁹</td>
<td>50 mg every 36 h for a total of 300 mg, followed by daily dose of 25 mg</td>
<td>600 mg (weight NR)</td>
<td>1/50 years/M</td>
<td>Single ulcer at base of finger</td>
<td>Endemic resident</td>
<td>History of renal transplant and receiving dialysis; diabetes</td>
<td>Oral azithromycin</td>
<td>Brazil NR</td>
<td>1/1</td>
<td>9</td>
</tr>
<tr>
<td>Brown and others⁹</td>
<td>3.125 mg/kg/d or 200 mg/d for 7 days, followed by 200 mg biweekly for 3 weeks</td>
<td>41</td>
<td>1/19 years/M</td>
<td>6-cm ulcer on left knee and 2 nodules on right hand</td>
<td>Non-immune returned traveler</td>
<td>No</td>
<td>No</td>
<td>Belize</td>
<td>L. (Viannia) braziliensis</td>
<td>1/1</td>
</tr>
<tr>
<td>Gündüz and others¹⁰</td>
<td>3 mg/kg/d biweekly for 6 weeks</td>
<td>36</td>
<td>1/60 years/F</td>
<td>3-year history of extensive facial plaque (leishmaniasis recidivans)</td>
<td>Endemic area resident</td>
<td>No</td>
<td>Pentavalent antimony and ketoconazole</td>
<td>Turkey NR</td>
<td>L. tropica</td>
<td>0/1, inadequate clinical response</td>
</tr>
<tr>
<td>Mirzabeigi and others¹¹</td>
<td>5 mg/kg/d for 2 months</td>
<td>300</td>
<td>1/50 years/F</td>
<td>Multiple painful nodules on both lower extremities 2 months after transplant surgery (reactivation)</td>
<td>Resident of Bolivia, immigrated to USA</td>
<td>History of renal transplantation and receiving immunosuppressive drugs</td>
<td>No</td>
<td>Bolivia</td>
<td>NR</td>
<td>1/1</td>
</tr>
<tr>
<td>Paradisi and others¹²</td>
<td>3 mg/kg/d on days 1–5, 14, and 21</td>
<td>21</td>
<td>1/56 years/M</td>
<td>Three large leg ulcers</td>
<td>Endemic area resident</td>
<td>Type II diabetes; lesions previously treated with topical steroids</td>
<td>Topical paromomycin and itraconazole</td>
<td>Italy</td>
<td>L. infantum</td>
<td>1/1</td>
</tr>
<tr>
<td>Rapp and others¹³</td>
<td>3 mg/kg/d on days 1–5 and 10</td>
<td>18</td>
<td>1</td>
<td>4-cm crusted lesion on left elbow for 3 years</td>
<td>Non-immune returned traveler</td>
<td>No</td>
<td>Pentavalent antimony and ketoconazole</td>
<td>Djibouti NR</td>
<td>NR</td>
<td>1/1</td>
</tr>
<tr>
<td>Rongioletti and others¹⁴</td>
<td>3 mg/kg/d for 5 days</td>
<td>15</td>
<td>1/82 years/M</td>
<td>Lip swelling for 2 years</td>
<td>Endemic area resident</td>
<td>No</td>
<td>Pentavalent antimony</td>
<td>Italy</td>
<td>L. infantum</td>
<td>1/1</td>
</tr>
<tr>
<td>Rosal and others¹⁵</td>
<td>5 mg/kg/d for 10 days</td>
<td>50</td>
<td>1/4 months/M and 19 years/M</td>
<td>3 cm hyperkeratotic nodule cheek; ulcers on jaw and right hand</td>
<td>Endemic area resident</td>
<td>No</td>
<td>Intrallesional pentavalent antimony plus topical imiquimod and amphotericin B; itraconazole</td>
<td>Spain, Bolivia, or Peru</td>
<td>1 NR, L. (Viannia) braziliensis</td>
<td>2/2</td>
</tr>
</tbody>
</table>

Continued
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment regimen</th>
<th>Total dose of AmBisome (mg/kg)</th>
<th>No patients evaluated/age/sex</th>
<th>Clinical manifestation</th>
<th>Disease endemic area resident or returned traveler (non-immune)</th>
<th>Immunocompromised</th>
<th>Prior anti-leishmanial drug treatment failure</th>
<th>Country in which acquired</th>
<th>Species</th>
<th>Clinical cure</th>
<th>Duration of follow-up (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Solomon and others&lt;sup&gt;16&lt;/sup&gt;</td>
<td>3 mg/kg/d on days 1–5 and 10</td>
<td>18</td>
<td>7, S/M and 2/F, age range = 21–24 years</td>
<td>Upper extremity ulcers (4) and facial ulcers (3) with lymph node enlargement</td>
<td>Non-immune returned travelers</td>
<td>No</td>
<td>5 pentavalent antimony treatment failure</td>
<td>Bolivia</td>
<td>L. (Viannia) braziliensis</td>
<td>7/7</td>
<td>3–17</td>
</tr>
<tr>
<td>Torre-Cisneros and others&lt;sup&gt;17&lt;/sup&gt;</td>
<td>1.5 mg/kg/d for 2 weeks, followed by 4 weekly doses of amphotericin B</td>
<td>31.5 mg</td>
<td>1/40 years/F</td>
<td>0.5–cm erythematous scaling lesion in right ear</td>
<td>Endemic area resident</td>
<td>No</td>
<td>2 initial treatment with Pentavalent antimony</td>
<td>Spain</td>
<td>NR</td>
<td>1/1</td>
<td>NR</td>
</tr>
<tr>
<td>Perez-Ayala and others&lt;sup&gt;18&lt;/sup&gt;</td>
<td>3 mg/kg/d on days 1, 14, and 21</td>
<td>21</td>
<td>1/27 years/M and 1/39 years/F</td>
<td>Two ulcers left thigh; one ulcer lower extremity</td>
<td>Immigrant; non-immune returned traveler</td>
<td>HIV+, No</td>
<td>0/2 side effects; inadequate clinical response</td>
<td>Burkina Faso, French Guiana</td>
<td>L. braziliensis</td>
<td>NR</td>
<td></td>
</tr>
</tbody>
</table>

* NR = not reported; HIV = human immunodeficiency virus.
AMBILOSE FOR TREATMENT OF CUTANEOUS LEISHMANIASIS

Table 2
Cohort description and outcome of patients with cutaneous leishmaniasis treated with amphotericin B (Ambisome)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (range)</td>
<td>29 (19–46)</td>
</tr>
<tr>
<td>Sex (% male)</td>
<td>95</td>
</tr>
<tr>
<td>Median no. lesions (range)</td>
<td>1 (1–11)</td>
</tr>
<tr>
<td>Median maximum lesion size, cm (range)</td>
<td>2 (1–5)</td>
</tr>
<tr>
<td>Countries of acquisition (number of cases)</td>
<td>Iraq (5), Afghanistan (5), Peru (1), French Guiana (1), Honduras (2), Columbia (6)</td>
</tr>
<tr>
<td>Strains of Leishmania recovered (number)</td>
<td>L. (Viannia) braziliensis (3), L. (V.) guyanensis (3), L. (V.) panamensis (4), L. tropica (2), L. major (3)</td>
</tr>
<tr>
<td>Median total dose of Ambisome for initial treatment course, mg and mg/kg (range)</td>
<td>1,748 (530–2,670), 21 (10–30)</td>
</tr>
<tr>
<td>Patients receiving a full treatment course</td>
<td>19</td>
</tr>
<tr>
<td>Patients with a cure after initial treatment regimen</td>
<td>16/19 (84%)</td>
</tr>
<tr>
<td>Median cumulative dose of Ambisome prescribed for 3 patients not healing with an initial treatment course, mg and mg/kg (range)</td>
<td>3,146 (3,000–3,430), 36 (33–42)</td>
</tr>
</tbody>
</table>

The initial treatment regimen for Ambisome was 3 mg/kg/day for a median number of 7 doses (range = 2–10 doses) and a median total dose of 1,748 mg (range = 530–2,670 mg). By milligrams/kilogram, the median total treatment dose was 21 mg/kg (range = 6–30 mg/kg). Thirteen patients (65%) had documentation of at least one adverse reaction to Ambisome. Five (25%) patients experienced infusion-related reactions, with development of chest pain, dyspnea, flank pain, flushing, and/or urticaria. For one patient, Ambisome was stopped after two doses because of these side effects, and the remaining patients tolerated further infusions. Some evidence of renal toxicity developed in 9 (45%) patients; 8 had a grade 1 toxicity value and 1 had a grade 2 toxicity value. Creatinine levels were either normalized (2 patients) or were returning to normal (4 patients) at time of discharge from medical care. Three patients did not return for follow-up laboratory testing.

Excluding one patient who received only two doses of Ambisome secondary to an acute infusion-related reaction and who then received treatment with Pentostam, 19 patients were included in the efficacy analysis. Median length of follow-up was 4 months (range = 1–27 months). Sixteen (84%) patients experienced a cure of their skin lesion after receiving an initial treatment course of Ambisome. Unfortunately, lack of standardized follow-up time points (caused by re-deployment of patients to combat zones or delay in responding to the queries of the investigators) prevented determination of a time to cure after administration of Ambisome. An illustrative example of a patient with L. (V.) braziliensis who experienced a cure after receiving seven doses of Ambisome is shown in Figure 1.

Three patients (16%) required additional doses of Ambisome for cure of their lesions. The median total dose of Ambisome given during the initial treatment course was 1,750 mg (range = 1,260–2,670 mg) for those patients who were cured with one course of Ambisome and 1,745 mg (range = 1,250–2,002 mg) for those who required a second course. Of those patients who required a second course, one patient with L. (V.) braziliensis acquired in Honduras initially experienced healing of his single skin lesion (4 × 2.5 cm) after 5 doses totaling 1,250 mg (doses 6 and 7 were not given because of development of gastroenteritis), but subsequent re-ulceration at the same site developed approximately 6 weeks after his treatment course. The patient was re-treated with a seven-dose regimen of Ambisome (re-treatment dose = 1,750 mg [21 mg/kg], with a cumulative dose of 3,000 mg [36 mg/kg]) with subsequent clinical cure. Two patients with L. (V.) panamensis acquired in Columbia were treated with seven doses of Ambisome each (total doses = 1,745 mg and 2,002 mg [21 mg/kg]) with transient improvement in their solitary lesions (1 × 1 cm and 2 × 2 cm). Both lesions failed to completely heal, but were successfully cured with seven and four dose re-treatment courses of Ambisome (cumulative doses = 3,430 mg [42 mg/kg] and 3,146 mg [33 mg/kg], respectively) approximately 10 weeks and 7 months, respectively, after the initial treatment course. One patient refused more than four additional doses of Ambisome because of infusion-related reactions, but nonetheless experienced healing of his lesion.

DISCUSSION

Our results demonstrate that Ambisome is an efficacious treatment for CL. Although encompassing a small number of patients, this study represents the largest published cohort of patients treated with Ambisome for CL to date. In addition, our study encompasses greater diversity than prior reports and describes disease acquired in five countries with five different strains of Leishmania. Sixteen (84%) of 19 patients were cured with an initial course of Ambisome. The 16% failure rate and the fact that the three failures were successfully treated with a second course of Ambisome suggests that the optimum dosing regimen for treatment of CL with Ambisome is still undefined.

In this study, administration of Ambisome was associated with mild-to-moderate toxicity; thus, this drug should be administered with caution. Acute infusion–related reactions associated with liposomal amphotericin B have been described, and a recent review reported a frequency of 20%, which is similar to the rate observed in this study.23 Nephrotoxicity is a recognized complication of therapy with Ambisome, and 45% of patients in our study experienced some evidence of renal dysfunction as measured by Common Terminology Criteria. Fortunately, renal dysfunction among our cohort was mild and transient. However, careful monitoring of renal function during therapy is prudent.

A direct comparison between Ambisome and the gold standard treatment of Pentostam was not conducted as part of this study, but previous studies have reported similar cure rates with Pentostam (depending on the patient population and geographic locale). Toxicity was observed with the administration of Ambisome, but Pentostam has its own host of recognized
side-effects. A prospective, randomized controlled study comparing AmBisome and Pentostam would be required to more clearly establish the strength and quality of the evidence base to support a recommendation to use AmBisome in non-immune returned travelers. However, the low numbers of patients in the United States receiving CL each year would necessitate a long-term, multi-site, and multi-national effort that would be costly and unlikely to be undertaken. Given our results, one could argue that such a study is not needed because AmBisome, although not the panacea for CL, appears to be efficacious for CL caused by several different infecting strains.

Unfortunately, the expense (pharmacy cost of $821 per 218-mg dose or approximately $6,500 for the median dose in our cohort of 1,748 mg) and potential toxicity of AmBisome argue that an improved therapy for CL is still needed, with perhaps an inexpensive, well-tolerated oral regimen as the goal. Because AmBisome is a costly off-label therapy in the United States, some insurance and health care plans may be reluctant to reimburse for the cost of treatment. However, alternatives are limited. Pentostam is provided free of charge to requesting civilian physicians by the Centers for Disease Control and Prevention and to Department of Defense beneficiaries by the U.S. Army, but this drug carries the cost of regulatory oversight and has defined toxicities, and there are increasing reports of therapeutic failures with pentavalent antimonial drugs.24, 25 In addition, although Pentostam can be administered in the outpatient setting, some providers may not have access to an infusion clinic, necessitating hospitalization for approximately three weeks. This cost and that of laboratory toxicity testing add to the expense of Pentostam. Oral agents (such as miltefosine and azole antifungal medications) have variable efficacy, may not be readily available, or are not FDA approved for a CL indication. Local destructive therapies (such as cryotherapy and the Thermomed® device) (Thermosurgery Technologies, Inc., Phoenix, AZ) are, in the authors’ opinion, unsuitable for large lesions. Other lipid-associated amphotericin B products have extremely limited data for use in CL in humans, and animal data have demonstrated variable efficacy among the different products.26 There is also a single case report of a treatment failure for CL with amphotericin B lipid complex.27 At this time, there is insufficient information to recommend any other lipid-associated amphotericin B formulation for treatment of CL.

The limitations of our data reflect the demographic characteristic of our adult military population (19 of 20 male patients). Thus, we have data for only one female patient and no children. In addition, the U.S. military population is otherwise healthy, well nourished, and immunocompetent. The efficacy of all drug treatments for immunocompromised patients is likely to be lower.

Faced with a multitude of less-than-optimal choices, we suggest the following strategy for the treatment of CL in otherwise healthy non-immune returning travelers. For patients with small lesions (< 1 cm) caused by strains of *Leishmania* that often self-heal (such as *L. mexicana* and *L. major*), the best therapy may be no therapy because the risks of treatment may outweigh the benefits.1 Local treatments such as cryotherapy, the Thermomed® device, and intra-lesional Pentostam (as practiced in some locations outside the United States) may be appropriate for limited disease. Therapy with Pentostam or AmBisome could be offered to patients with cosmetically concerning lesions (e.g., on the face), or with strains of *Leishmania* that self-heal slowly or that can metastasize (such as *L. tropica* and *L. (V). braziliensis*). Our experience suggests that AmBisome be considered as an option for initial therapy in patients requiring systemic therapy for CL. The optimal regimen (daily dose and schedule) for each infecting strain of

![Figure 1. Patient with cutaneous leishmaniasis caused by *Leishmania (Viannia) braziliensis* baseline and three weeks and five months after treatment with seven doses of AmBisome. This figure appears in color at www.ajtmh.org.](image-url)
Leishmania has not been determined, but the current FDA-approved regimen for the treatment of visceral leishmaniasis in immunocompetent patients of 3 mg/kg/day on days 1–5, 14, and 21 (21 mg/kg) is a reasonable starting point for most patients. The day 14 and 21 dose may not be logistically feasible for some patients, and administering the total dose of 21 mg/kg over a shorter period can be considered.

Received March 23, 2010. Accepted for publication July 2, 2010.

Acknowledgments: We thank Kelly Hummer, Cyrilla Smalls, and Angela Tyler for their outstanding nursing support.

Disclaimer: The views expressed in this article are those of the authors and do not reflect the official policy of the Department of Army, the Department of Defense, or the US Government.

Authors’ addresses: Glenn Wortmann, Michael Zupor, Roseanne Resnner, Susan Fraser, Joshua Hartzell, Amy Weintrob, Infectious Diseases Clinic, Washington, DC, E-mail: glenn.wortmann@us.army.mil.

E-mail: joe.c.pierson@afghan.swa.army.mil.

Alan Magill, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, E-mail: alan.magill@us.army.mil.

REFERENCES


